Valuation: Alligator Bioscience AB

Market Cap 25.38M 2.68M 2.32M 2.16M 1.98M 3.73M 255M 3.79M 9.96M 128M 10.05M 9.83M 422M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 25.38M 2.68M 2.32M 2.16M 1.98M 3.73M 255M 3.79M 9.96M 128M 10.05M 9.83M 422M EV / Sales 2026 *
0.64x
EV / Sales 2027 * 4.3x
Free-Float
75.08%
Yield 2026 *
-
Yield 2027 * -
1 day-5.94%
1 week-10.28%
Current month-10.28%
1 month-78.67%
3 months-81.13%
6 months-80.62%
Current year-88.60%
1 week 0.04
Extreme 0.0365
0.04
1 month 0.03
Extreme 0.0324
0.25
Current year 0.03
Extreme 0.0324
0.49
1 year 0.03
Extreme 0.0324
5.6
3 years 0.03
Extreme 0.0324
1,568
5 years 0.03
Extreme 0.0324
7,200
10 years 0.03
Extreme 0.0324
40,100
Manager TitleAgeSince
Chief Executive Officer 55 2021-05-31
Director of Finance/CFO 61 2024-08-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 2021-05-31
Director/Board Member 68 2022-05-08
Date Insider Type Main position Quantity % Market Cap.
3/5/25 Buy

Chairman

800,000 0.0047%
3/5/25 Buy

Chairman

77,319 0.0005%
3/5/25 Sell

Chairman

1,658,134 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-4.95%-10.28%-99.25%-99.99% 2.67M
+0.99%+1.78%+4.07%+16.73% 48.7B
+1.81%+6.35%+470.64%+572.87% 42.05B
+1.83%+0.48%+31.96%+7.68% 38.26B
+4.74%+9.32%+15.82%+84.23% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+1.76%+4.27% - - 16.47B
-0.20%+1.07%+36.03%+124.01% 16.33B
-0.11%+2.41%+6.24%+18.87% 13.98B
-1.52%+12.68%+74.92%+27.63% 12.68B
Average +0.55%+2.58%+61.96%+89.30% 25.74B
Weighted average by Cap. +1.75%+2.31%+99.50%+135.39%

Financials

2026 *2027 *
Net sales 39.9M 4.21M 3.64M 3.4M 3.12M 5.87M 401M 5.96M 15.66M 201M 15.81M 15.46M 664M 5.9M 623K 538K 503K 461K 868K 59.25M 881K 2.32M 29.7M 2.34M 2.29M 98.18M
Net income -36.3M -3.83M -3.31M -3.09M -2.84M -5.34M -365M -5.42M -14.25M -183M -14.38M -14.07M -604M -69.9M -7.38M -6.38M -5.96M -5.47M -10.28M -702M -10.44M -27.44M -352M -27.7M -27.09M -1.16B
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
26-08-07 SEK 0.0384 -4.95% 12,006,918
26-08-06 SEK 0.0404 -4.27% 9,424,228
26-08-05 SEK 0.0422 -0.47% 4,397,479
26-08-04 SEK 0.0424 -0.93% 8,092,411
26-08-03 SEK 0.0428 0.00% 4,848,574
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATORX Stock